1. Home
  2. ALLT vs CCCC Comparison

ALLT vs CCCC Comparison

Compare ALLT & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Allot Ltd.

ALLT

Allot Ltd.

HOLD

Current Price

$6.38

Market Cap

519.6M

ML Signal

HOLD

Logo C4 Therapeutics Inc.

CCCC

C4 Therapeutics Inc.

HOLD

Current Price

$2.72

Market Cap

185.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALLT
CCCC
Founded
1996
2015
Country
Israel
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
519.6M
185.1M
IPO Year
2006
2020

Fundamental Metrics

Financial Performance
Metric
ALLT
CCCC
Price
$6.38
$2.72
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
6
Target Price
$12.25
$12.20
AVG Volume (30 Days)
695.5K
2.8M
Earning Date
02-25-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
16.45
EPS
N/A
N/A
Revenue
N/A
$35,947,000.00
Revenue This Year
$15.84
N/A
Revenue Next Year
$12.08
N/A
P/E Ratio
$469.21
N/A
Revenue Growth
N/A
1.02
52 Week Low
$4.37
$1.09
52 Week High
$11.92
$3.82

Technical Indicators

Market Signals
Indicator
ALLT
CCCC
Relative Strength Index (RSI) 29.38 51.50
Support Level $6.20 $2.35
Resistance Level $8.10 $2.71
Average True Range (ATR) 0.28 0.26
MACD 0.05 -0.07
Stochastic Oscillator 7.32 13.07

Price Performance

Historical Comparison
ALLT
CCCC

About ALLT Allot Ltd.

Allot Ltd is a provider of network intelligence and security solutions for service providers and enterprises. The company's solutions are deployed globally for network and application analytics, traffic control and shaping, and network-based security services. The firm's multi-service platforms are deployed by mobile, fixed, and cloud service providers and enterprises. The company has a customer base in Europe, Asia and Oceania, the Americas, the Middle East, and Africa.

About CCCC C4 Therapeutics Inc.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.

Share on Social Networks: